IDXX

IDXX

USD

IDEXX Laboratories Inc. Common Stock

$471.900-8.270 (-1.722%)

Reaalajas hind

Healthcare
Diagnostics & Research
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$480.170

Kõrge

$483.910

Madal

$466.570

Maht

0.12M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

38.0B

Tööstusharu

Diagnostics & Research

Riik

United States

Kauplemisstatistika

Keskmine maht

0.86M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $356.14Praegune $471.900Kõrge $548.88

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 30. apr 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

IDXX: IDEXX Laboratories Inc. Common Stock - What's Happening and What to Watch

Stock Symbol: IDXX Generate Date: 2025-04-30 19:57:31

Alright, let's break down what's been going on with IDEXX Laboratories, the company focused on pet healthcare and other diagnostics. We'll look at the recent news, how the stock price has been moving, and what some of the automated systems are predicting.

What the Latest News Tells Us

We've got a couple of recent news bits. First off, back on April 14th, an analyst over at Stifel kept their "Hold" rating on IDEXX. That's kind of a neutral stance, meaning they aren't strongly recommending buying or selling right now. However, they did trim their price target a bit, dropping it from $450 down to $420. Lowering a price target usually isn't seen as a super positive sign, even if the overall rating stayed neutral.

The other big piece of news, from April 3rd, is simply that IDEXX is getting ready to drop its first-quarter financial results for 2025. That's scheduled for tomorrow, May 1st, before the market even opens. Earnings reports are always a major event for any stock. They can send the price jumping or falling depending on whether the company beats or misses expectations, and what they say about the future. So, while the news itself is just a schedule announcement, the event is a really big deal right around the corner.

Putting the news together, it's a bit mixed. You have an analyst slightly less optimistic on the price target, but the real unknown is how the company performed in the last quarter, and we'll find that out very soon.

Looking at the Stock's Recent Journey

If you glance at the stock chart over the past few months, it's been quite a ride. The price was hanging out in the low to mid-$400s earlier in the year. Then, in early April, it took a pretty significant dip, hitting a low point around $356.

But here's the interesting part: since hitting that low around April 9th, the stock has bounced back quite strongly. It's been climbing steadily through the latter half of April and is now trading back up in the $430s. The closing price on April 30th was $432.60. That's a solid recovery from those recent lows.

Now, let's look at what the AI prediction model is saying for the very near future, starting from today's price. It predicts a small gain today (+0.91%), a larger gain tomorrow (+2.28%), and an even bigger jump the day after (+4.40%). These are pretty optimistic short-term predictions, suggesting the AI sees this recent upward trend continuing.

So, What's the Picture Looking Like?

Based on the data we have right now – the mixed news (analyst caution vs. upcoming earnings catalyst), the stock's recent strong bounce off its lows, and the AI model predicting further short-term gains – the apparent near-term leaning seems to be cautiously positive, but with a huge asterisk for the earnings report tomorrow.

The price action shows buyers stepped in aggressively after the early April drop. The AI prediction supports the idea that this upward momentum might continue for a couple more days.

If you were considering this stock, the current price area, roughly in the low to mid-$430s, seems to be the starting point for the AI's predicted move. The recommendation data we have also points to potential entry points around $434 and $437, which lines up with where the stock is trading now. This could be considered a potential area if you believe the recent trend and AI prediction have legs.

For managing risk, the recommendation data suggests a potential stop-loss level around $390.48. That's well below the recent price action and would be a point to consider cutting losses if the stock reverses course sharply, perhaps after the earnings report. On the upside, the recommendation data lists a near-term take-profit target around $442.55. The AI prediction is even more optimistic, projecting a potential target price of $475.42 over a slightly longer horizon. These could be levels to watch if the stock continues its climb.

Remember, the earnings report tomorrow is the wild card. Good results could fuel the rally, while disappointing results could easily send the stock back down.

Company Context

Just a quick reminder about IDEXX itself: they are a big player in the pet healthcare world, providing diagnostic products and services. They also work with livestock and water testing. This means their business performance is tied to things like how much people are spending on their pets' health and the demand for testing in other areas. The upcoming earnings will give us a clearer picture of how these parts of their business are doing.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can move rapidly. You should always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions. Investing in stocks involves risk, including the potential loss of principal.

Seotud uudised

BusinessWire

IDEXX Laboratories Announces First Quarter Results

Achieves first quarter revenue growth of 4% as reported and 5% organic, supported by CAG Diagnostics recurring revenue growth of 3% as reported and 4.5% organic. Organic revenue growth supported by benefits from

Vaata rohkem
IDEXX Laboratories Announces First Quarter Results
Analyst Upgrades

Stifel Maintains Hold on IDEXX Laboratories, Lowers Price Target to $420

Stifel analyst Jonathan Block maintains IDEXX Laboratories with a Hold and lowers the price target from $450 to $420.

Vaata rohkem
Stifel Maintains Hold on IDEXX Laboratories, Lowers Price Target to $420

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Tõusev

Uuendatud kell: 3. mai 2025, 09:14

LangevNeutraalneTõusev

75.9% Kindlus

Risk ja kauplemine

Riskitase3/5
Keskmine risk
Sobib
Konservatiivne
Kauplemisjuhend

Sisenemispunkt

$471.51

Võta kasum

$500.96

Peata kahjum

$424.67

Põhitegurid

PDI 6.4 on MDI 4.9 kohal ADX-iga 11.0, mis viitab tõusutrendile
Praegune hind on tugitasemele ($470.37) äärmiselt lähedal, mis viitab tugevale ostuvõimalusele
Kauplemismaht on 5.5x keskmisest (10,231), mis viitab äärmiselt tugevale ostusurvele
MACD 0.2645 on signaalijoone 0.0408 kohal, mis viitab tõusvale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.